Dr. Castillo, co-author of an international cooperative paper in the Journal of Neuro-Ophthalmology

Medical content revised by - Last revision 09/11/2021
Dr. Castillo, co-author of an international cooperative paper in the Journal of Neuro-Ophthalmology

Dr. Lorena Castillo, head of the ICR Neuro-Ophthalmology Department and opinion leader on LHON – Leber’s Hereditary Optic Neuropathy – has co-authored an international study published in the prestigious American Journal of Neuro-Ophthalmology.

The research, entitled Real-World Clinical Experience With Idebenone in the Treatment of Leber Hereditary Optic Neuropathy, analyzes the efficacy and safety of Idebenone in patients with LHON in whom treatment has been initiated within a period of no more than 1 year from the onset of visual loss of the second eye.

What is Idebenona for?

Leber Hereditary Optic Neuropathy is a rare pathology caused by a mutation in the mitochondria, which consequently damages the optic nerve and causes a severe loss of vision.

There is no cure for this disease today. However, certain medicines that delay the progression of the disease are being studied. One example is Idebenone, a medicine similar in structure to the natural antioxidant coenzyme Q10, which aims to reactivate the proper functioning of mitochondria and prevent damage to the eye nerve.

Idebenone is considered an orphan medication, since it is used to treat rare diseases, that is, diseases that affect a small group of the population.

L’Agència Espanyola del Medicament (AEMPS) ha autoritzat fins a 108 fàrmacs orfes, dels quals se’n comercialitzen 58.
The Spanish Medicines Agency (AEMPS) has authorized up to 108 orphan medicines, of which 58 are on the market.

The international study evaluates the effectiveness of the treatment

In this research, the safety and efficacy of Idebenone was studied in 111 and 87 patients, respectively, from 10 different countries.

The study confirms the safety of Idebenone and suggests that a percentage of patients treated with this drug have a better long-term prognosis, as well as that the response to the drug increases if the disease is treated early. This study also indicates that treatment must last at least 24 months in order to obtain positive results.

You can read the full article below:

Real-World Clinical Experience With Idebenone in the Treatment of Leber Hereditary Optic Neuropathy. Journal of Neuro-Ophthalmology: December 2020

Related articles

ICR Research Department is carrying out a clinical trial lead by Dr. Castillo with patients affected by LHON

ICR, at the forefront of research Dr Castillo, Head of Neuro-Ophthalmology and Teaching Department at Institut Català de Retina, has initiated, alongside the Research Department, a clinical trial developed by Santhera Pharmaceuticals, for which participants affected by Leber Optic Neuropathy (LHON), older than 12 years old and of all genders, are being recruited. The disease must […]

Dr. Castillo leads a study in Spain to learn more about the natural history of the LHON

GenSight starts a study to better understand the natural history of Leber’s hereditary optic neuropathy (or LHON) – how visual function evolves, what other symptoms can be associated … -, how genetic and environmental factors are related in the development of the disease and the direct or indirect costs for the patient and family. It is […]

La Dra. Castillo, ponent convidada al curs de formació continuada de la SEN

La Dra. Lorena Castillo, responsable del Departament de Neurooftalmologia d’ICR va ser convidada a participar com a ponent en el curs de formació continuada de la Sociedad Española de Neurología (SEN).

La Dra. Lorena Castillo parla sobre la LHON al programa “Enfermedades raras” de Libertad FM

La Dra. Castillo, experta en LHON, va parlar de com es presenta aquesta malaltia rara que afecta principalment a pacients joves i que produeix una ceguesa sobtada, així com dels possibles tractaments i teràpies que s’estan provant per tractar els afectats.

Do you have any questions?

Contact us or request an appointment with one of our Neuro-Ophthalmology specialists.

Visit us at:

ICR Pau Alcover

C. Pau Alcover 67
08017 Barcelona See map

ICR Ganduxer Headquarters

c/Ganduxer,117
08022 Barcelona See map

ICR Terrassa

77, Del Nord St.
08221 Terrassa See map

ICR Service at Clínica Ntra. Sra. del Remei

c/ de l'Escorial,148
08024 Barcelona See map

Clínica Bonanova Surgical Center

Passeig Bonanova, 22
08022 Barcelona See map

Clinica Bonanova Tests and Treatments

c/ Mandri, 63
08022 Barcelona See map

ICR Pau Alcover

Telephone number (+34) 93 378 23 19

Opening hours:
Monday to Friday from 8 am to 9 pm. Saturday from 8 am to 2 pm.

How to get there More information

ICR Ganduxer Headquarters

Telephone number 93 254 79 20
Emergencies phone number: 93 418 72 27

Opening hours:
Monday to Friday 8 a.m. to 9 p.m.
Saturdays 9 a.m. to 2 p.m.

How to get there More information

ICR Terrassa

Telephone number +34 93 736 34 40

Opening hours:
Monday to Friday from 8:30 a.m. to 2 p.m. and 3 p.m. to 8 p.m.

How to get there More information

ICR Service at Clínica Ntra. Sra. del Remei

Telephone number 902 10 10 50

Opening hours:
Every day from 3 p.m. to 8 p.m. and Friday mornings from 10 a.m. to 2 p.m.

How to get there More information

Clínica Bonanova Surgical Center

Telephone number 934 34 09 25

Opening hours:
Monday to Friday from 7:30 a.m. to 8:30 p.m.

How to get there More information

Clinica Bonanova Tests and Treatments

How to get there More information